INTERPRETATION Children born to mothers prescribed methadone in pregnancy are at risk of neurodevelopmental problems but risk of bias limits inference about harm. Research into management of opioid use disorder in pregnancy should include evaluation of childhood neurodevelopmental outcome.
Opioid use, both prescribed and illicit, has been increasing globally since 2007. Past-year prevalence of heroin use has almost doubled since 2007, and the rate of increase is higher among women compared with men. In the USA, the average rate of past-year heroin use between 2013 and 2015 was 2.0 per 1000 women, 1 and since 2000 there has been an almost fivefold increase in the prevalence of neonatal abstinence syndrome (NAS), a drug withdrawal syndrome commonly used as a proxy for opioid exposure during pregnancy. 2 It is estimated that in the current opioid crisis up to 14.4% of pregnant women have opioid prescriptions dispensed during pregnancy. 3 Pregnant women who use heroin are recommended medically assisted treatment (MAT) with an opioid substitute such as methadone as part of a comprehensive antenatal care plan because it is associated with improved use of antenatal services, reduced use of heroin during pregnancy, and reduced risk of preterm delivery, when compared with no treatment. [4] [5] [6] [7] [8] [9] Fetal benefits of MAT include improved growth 7, 10 and less risk of intrauterine death. 8 Methadone is a synthetic long acting l-opioid agonist which freely crosses the placenta; despite the potential for methadone to affect the developing fetal brain, this treatment was introduced into practice without a randomized controlled study of childhood neurodevelopmental outcome. Preclinical studies suggest that exogenous opioids may exert pleiotropic harmful effects on the central nervous system, [11] [12] [13] and diffusion magnetic resonance imaging studies show that the tract tissue microstructure of white matter (fractional anisotropy) is altered in neonates exposed prenatally to methadone. 14, 15 Improved understanding of the neurodevelopmental outcome of children born to opioid-dependent mothers and exposed prenatally to methadone is essential to inform management of their mothers during pregnancy. [16] [17] [18] The issue is prescient because the optimal methadone dose regimen is uncertain, 19 and alternative opioids such as buprenorphine may have a different risk profile for neonatal outcome, 16, 17, 20 leading to equipoise about the optimal MAT strategy.
The aims of this study were to perform a systematic review of published literature on childhood neurodevelopmental outcomes after prescription of maintenance methadone in pregnancy, and to undertake a meta-analysis of studies that used a common assessment tool.
METHOD
The study protocol was registered with the international prospective register of systematic reviews (PROSPERO), registration number CRD42017063987 (https://www.crd. york.ac.uk/prospero/). Methodology is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. 21 We included all studies that reported neurodevelopmental outcome, including visual development, of children whose opioid-dependent mothers were prescribed methadone during pregnancy. There was no language restriction. Exclusion criteria were prescription of alternative opioid substitutes during pregnancy and studies reporting only neonatal neurodevelopment.
Two reviewers (VJM, RH) independently searched MEDLINE, Embase, and PsycINFO for studies published between 1975 and 2017. Medical Subject Headings terms used were 'methadone' and 'prenatal' or 'prenatal exposure' or 'prenatal drug exposure' or 'prenatal exposure delayed effects' or 'in utero'. Bibliographies of primary studies and review articles meeting the inclusion criteria were searched manually to identify further eligible studies.
Three reviewers (VJM, RH, HM) independently screened titles and abstracts to identify potentially eligible studies. Where necessary to determine eligibility, full text was retrieved and reviewed. Duplication was avoided if it was clear that the same cohort was reported in two publications; where more than one publication for a study was retrieved, only the report that contained the maximum data points was included.
Four reviewers (VJM, RH, HM, JPB) independently extracted data from included studies using a standardized template. Extracted information included study setting, design, population and participant demographics, details of methadone exposure if available, control conditions, recruitment and completion rates, age at outcome measurement, assessment tool, and outcome of assessment. Data were extracted from each study by two reviewers independently, and templates were combined to ensure complete data collection. Disagreements were resolved through discussion.
A quality assessment instrument was developed using the Grading of Recommendations Assessment Development and Evaluation Guidelines [22] [23] [24] to provide a structured scoring system that aimed to describe quality and sources of bias in studies of neurodevelopment after prenatal drug exposure. It incorporated objective criteria about study design, sample size and characteristics, use of validated outcome measures, risk of bias (blinding, confounding, attrition), and data analysis. Each study was assessed independently by two reviewers (VJM, JPB) and scored as good (A, 6.5-8), intermediate (B, 3.5-6), or poor (C, 1-3) quality (Table SI , online supporting information).
Statistical analysis
Where studies used the same assessment tool for any outcome domain, quantitative data were pooled in random effects meta-analysis using R software, version 3.2.2 (K Hornik; R Foundation for Statistical Computing, Vienna, Austria; https://cran.r-project.org/) with mean difference weighted by the inverse of the variance. 25 Effect sizes were expressed as weighted mean differences (WMD) and their 95% confidence intervals (CI). For longitudinal studies, data for assessments at 6 months and at 2 years were analysed. Heterogeneity was assessed using the standard I 2 and s statistics and graphically using forest plots. Where statistical pooling was not possible, data were collated in tables for outcomes across two domains (neurodevelopmental and visual development), and statements generated to represent the body of literature reviewed.
RESULTS

Characteristics of included studies
Forty-one eligible studies were identified, including a total of 1441 methadone-exposed children and 842 unexposed children (Fig. S1 , online supporting information). Twentynine studies reported neurodevelopmental outcome (1247 methadone-exposed vs 740 unexposed children), eight of which were amenable to meta-analysis; 12 reported visual outcome (275 methadone-exposed vs 128 unexposed). There were no randomized trials.
Only one study fulfilled criteria for good quality; 26 26 (63%) studies were intermediate and 14 (34%) were poor quality (Table SI) . Study deficiencies included lack of blinding, small sample size, high attrition rates, and lack of comparison group validity. Twenty-four of 41 studies reported information about polydrug use during pregnancy, and 20 studies provided information about methadone dose exposure.
Thirty-three of 41 studies reported infants receiving pharmacological treatment of NAS; in 19 of these the treatment regimen was described, with the most frequently What this paper adds
• Children born to opioid-dependent mothers prescribed methadone are at risk of neurodevelopmental impairment.
• Exposed infants have lower Mental Development Index and Psychomotor Development Index scores than unexposed children.
• Atypical visual evoked potentials, strabismus, and nystagmus have increased prevalence.
• Estimates of impairment may be biased by intermediate to poor quality evidence.
Review 751 used drugs being morphine, phenobarbital, benzodiazepines, or a combination. Sixteen studies stated that infants born preterm were included, while only seven explicitly excluded infants born before 36 weeks' gestation. In 18 studies, it could not be determined whether infants born preterm were included.
Neurodevelopmental outcome
Of 29 studies reporting neurodevelopmental outcome, 15 used the original Bayley Scales of Infant Development. 27 Five of these 15 studies had no comparison individuals, [28] [29] [30] [31] [32] one did not report a measure of variance, 33 and one assessed children at 9 months only; 34 leaving eight studies that were eligible for meta-analysis of neurodevelopmental outcome based on the Bayley Scales of Infant Development (Table I) .
Five studies reported Mental Development Index (MDI) at 6 months of age, [35] [36] [37] [38] [39] and four of these reported Psychomotor Development Index (PDI) [35] [36] [37] 39 ( Fig. 1 ). Studies were all of intermediate quality with attrition rates ranging from 31% to 70%; three studies described maternal methadone doses, and gestational age was variably reported. For both MDI and PDI at 6 months, the difference in exposed versus non-exposed infants was marginal and 95% CIs included the possibility of no difference: MDI, WMD of À1.56 (95% CI À4.98 to 1.87; Fig. 1a) ; PDI, WMD of À2.46 (95% CI À6.75 to 1.82; Fig. 1b) .
Seven studies reported MDI at 2 years of age, [36] [37] [38] [39] [40] [41] [42] four of which reported PDI 36, 37, 39, 42 (Table I ). All seven studies were rated intermediate quality, with attrition rates ranging from 18% to 84%; maternal methadone dose was variably reported; and where polydrug use was reported (five of seven studies), this ranged from 56% to more than 90% of mothers. The gestational age of participants was not stated in four studies. 38, [40] [41] [42] Five studies reported rates of NAS between 67% and 92%; and no study described treatment for NAS. Compared with non-exposed children, methadone exposure was associated with lower MDI, WMD of À4.43 (95% CI À7.24 to À1.63; Fig. 2a) , and lower PDI, WMD of PDI À5.42 (95% CI À10.55 to À0.28; Fig. 2b ).
Of the remaining 21 neurodevelopmental studies, 13 were rated as having intermediate quality and eight as poor quality. Infant Behavior Record was reported in two studies: Marcus et al. reported poorer motor performance at 4 months in 15 methadone-exposed infants compared with 23 unexposed infants; 43 and Wilson et al. 34 matched 33 methadone-exposed infants with 55 unexposed infants for maternal age, ethnicity, socio-economic status, and marital status, and reported poorer fine motor coordination, less attentiveness, and lower motor scores on the Bayley Scales of Infant Development at 9 months of age, but no difference in cognitive scores. Schneider and Hans reported no difference in focused attention during free play at 24 months between 30 exposed and 44 unexposed toddlers. 44 Suffet et al. 30 reported MDI and PDI in the normal range at 1 year, with females performing better than males (MDI mean 108.8 vs 102.7, p<0.05; PDI mean 102.3 vs 95.7, p<0.05). This association persisted for cognition up to 2 years of age (MDI 99.2 vs 82.0, p<0.01). Bier et al. 45 reported MDI scores in the normal range at 4 months of age, in a cohort of 165 methadone-exposed infants, with no difference between those infants exposed prenatally to either low dose (<100mg/d) or high dose (≥100mg/d) methadone.
At 6 months of age, using the Griffiths Scales of Mental Development, McGlone et al. 46 noted reduced median scores across all domains which persisted after adjustment for prenatal alcohol exposure and maternal smoking. This study included 81 methadone-exposed infants and 26 nondrug-exposed infants, matched for gestation and socio-economic status. Scores were also lower for infants who had been treated for NAS (median general quotient 95 vs 99, p<0.008). Bunikowski et al. 47 reported reductions in quotients for two subscales (hearing and speech; intellectual performance) at 1 year of age in a case series of 18 prenatally exposed infants compared with 42 unexposed children.
Twelve studies evaluated children older than 2 years using a range of assessment tools (Table II) . Participants included 323 methadone-exposed children and 321 unexposed children.
Six out of 10 studies measuring cognitive outcomes reported no difference between methadone-exposed and unexposed children, 37, 38, 41, [48] [49] [50] and four studies reported lower cognitive performance in methadone-exposed children at 2 years 6 months, 39 3 years, 51 3 years 6 months, 52 4 years 6 months, 52 5 years 6 months, 52 and 8 years 6 months 53 respectively. The Reynell Developmental Language Scales were used in two studies (93 methadoneexposed vs 76 unexposed children) at 3 years 51 and at 4 years; 52 both reported reduced performance in expressive and comprehensive language. Of the seven studies assessing behaviour, six reported more behavioural problems in methadone-exposed children than in unexposed children. 41, [50] [51] [52] 54, 55 Details of all studies reporting childhood neurodevelopmental outcome after prenatal methadone exposure are summarized in Table SII (online supporting  information) .
Visual development and function
Twelve studies reported visual outcomes, five of which measured visual evoked potentials (VEPs; Table SIII, online supporting information). The VEP studies consisted of a total of 143 methadone-exposed and 103 unexposed children, with one rated poor quality, three rated intermediate, and one rated good quality.
In two different cohorts, flash VEPs at 1 day to 4 days after birth were more frequently absent or immature and were smaller on average in methadone-exposed infants compared with non-exposed newborns. 56, 57 At 4 months 58 and at 6 months of age, 26 pattern-reversal and patternonset VEP abnormalities persisted in methadone-exposed infants. One follow-up study of 10 3-year-old children previously tested at 4 months found no group difference in pattern-reversal VEP peak times. Review 753 A further six case series have described abnormal visual outcomes in a total of 108 methadone-exposed children [60] [61] [62] [63] [64] [65] (Table SIV, online supporting information). All six studies were rated as having poor quality evidence because they did not have comparison groups and did not correct for confounders owing to their observational design. However, collectively they describe common visual abnormalities, nystagmus (50 out of 108) and strabismus (51 out of 108), which may occur together (22 out of 108 cases). Nystagmus in all described cases was horizontal and either jerk or pendular in waveform.
In a case-control study of 100 methadone-exposed infants, 81 of whom were followed up at 6 months of age, abnormal visual outcomes were present in 40% of methadone-exposed children (nystagmus nine out of 81 cases, strabismus 20 out of 81 cases; both five out of 81) compared with two out of 26 non-drug exposed infants matched for gestation and socio-economic status. 26 One intermediate quality study of methadone-exposed 4-yearold children reported reduced visual selective attention in methadone-exposed children compared with unexposed children. 66 
DISCUSSION
This systematic review of neurodevelopmental and visual outcomes of children born to opioid-dependent mothers prescribed methadone in pregnancy has synthesized data from 41 studies (1441 children whose mothers were prescribed methadone and 842 children whose mothers were not prescribed methadone during pregnancy). In the metaanalysis, we found that point estimates of MDI and PDI in children exposed to prenatal methadone compared with children whose mothers were not prescribed methadone are reduced at 6 months of age, and by 2 years the 95% CIs of these estimates make the possibility of no group difference in MDI and PDI unlikely. The emergence of difficulties as children grow older is well-recognized after complications during the perinatal period and is likely to reflect the ontogeny of higher-order functions through childhood. The finding of behavioural problems in six out of seven studies that measured this domain, and lower cognitive performance in four out of 10 studies that reported outcome after 2 years, suggests that children of opioiddependent mothers prescribed methadone may be at increased risk of longer-term problems.
An association between prenatal methadone exposure and atypical visual development has been described, with significant differences in VEPs in infancy and childhood, reflecting altered visual pathways. 56, 58 McGlone et al., 26 in their cohort of 81 methadone-exposed and 29 unexposed infants at 6 months of age, describe a methadone-attributable risk of abnormal visual assessment of 80%, after correcting for excess prenatal alcohol exposure. The prevalence of childhood strabismus and nystagmus in the methadone-exposed population is higher than expected, which suggests that disorders of childhood visual function, as well as altered electrophysiological measures, are associated with prenatal methadone exposure.
Our findings are consistent with a recent meta-analysis of five studies of infants and preschool children exposed to chronic intrauterine illicit heroin and/or prescribed methadone, which reported neurobehavioural impairment in the opioid-exposed group. 67, 68 Our data provide additional information by focusing on studies of women prescribed methadone, analysis of studies that reported a wide range of outcomes including visual development, and inclusion criteria designed to achieve maximum representation of the target population. Specifically, because use of prescribed and non-prescribed drugs and tobacco is common among pregnant women prescribed methadone (but ascertainment and reporting of polydrug exposure in studies is variable), 69 and because our purpose was to determine outcomes of methadone-exposed children rather than to investigate causation, we took a pragmatic approach and did not attempt to exclude on the basis of polydrug use.
The data are also consistent with the observation that fractional anisotropy is reduced throughout the white matter skeleton of neonates born to mothers who were prescribed methadone, 15 because neonatal fractional anisotropy is associated with later neurodevelopmental impairment. 70, 71 More broadly, these results contribute to an emerging literature suggesting that exposure of the brain to psychoactive drugs during the perinatal period may modify its development. 72, 73 A strength of this work is its pragmatic and systematic approach to summarizing childhood neurodevelopmental outcome after prescribed prenatal methadone exposure. We excluded studies of neonatal neurodevelopment to prevent confounding by NAS, and we excluded studies of alternative opioid substitutes to derive maximum inference about methadone.
However, limitations of included studies mean that the risk of impairment in children whose mothers were prescribed methadone may be biased. In particular, comparison groups were often poorly described beyond the definition of 'non-opioid exposed', with inadequate control for socio-economic status, or environmental factors, making it difficult to know who the methadone-exposed children were being compared with. Reporting of maternal methadone dosing and polydrug or alcohol use was variable and therefore it was difficult to obtain an accurate exposure profile of included children; only one study examined prenatal exposure in all infants in detail using extensive toxicology. 57 Finally, only 15 of the 41 studies were published in the past decade, which might affect application of results to contemporary populations because patterns of drug misuse change over time and strategies for MAT of opioid use disorder in pregnancy have evolved. For example, the dose of methadone prescribed for MAT in current practice is typically higher than that reported in historical studies. Further study of contemporary populations is required to determine the neurodevelopmental and Review 755 visual outcomes of children born to opioid-dependent mothers. Improved understanding of the effects of prenatal opioid use disorder and its treatment, including the use of alternative substitutes, has been identified as a research priority. 74 Buprenorphine has been evaluated as an opioid substitute in pregnancy. Although less severe NAS, improved growth, shorter hospital stay, and longer gestation are all reported in buprenorphine-exposed compared with methadone-exposed infants, 16, [75] [76] [77] a recent Cochrane review concluded that there are insufficient data to establish whether buprenorphine is equivalent for all maternal outcomes, including adherence to treatment. 18 Furthermore, confounding by indication could explain improved neonatal outcomes in buprenorphine groups. 17 Therefore, there remains clinical equipoise about the safest opioid substitute for mother and child.
The data presented highlight that being born to an opioid-dependent mother who has been prescribed 35 Rosen et al. 37 Chasnoff et al. 36 Kaltenbach et al. 38 van 35 Rosen et al. 37 Chasnoff et al. 36 Review 757 maintenance methadone in pregnancy is associated with adverse visual and neurodevelopmental outcomes in infancy and early childhood, but deficiencies in the existing literature limit causal inference about harm and factors other than methadone per se could account for these observations. Further research into optimal management of opioid-dependent pregnant women is required; future studies should consider fetal brain development and long term neurodevelopmental and visual outcomes of the child.
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